Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor

J Clin Oncol. 2016 Apr 10;34(11):e99-e103. doi: 10.1200/JCO.2012.44.7300. Epub 2014 Dec 29.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Wall / pathology
  • Adult
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Disease Progression
  • Drug Administration Schedule
  • Female
  • Gastrointestinal Stromal Tumors / genetics*
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / secondary
  • Germ-Line Mutation
  • Humans
  • Imatinib Mesylate / administration & dosage
  • Imatinib Mesylate / therapeutic use*
  • Mutation*
  • Paraganglioma / genetics*
  • Paraganglioma / pathology
  • Paraganglioma / secondary
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-kit / genetics*
  • Receptor, Platelet-Derived Growth Factor alpha / genetics*
  • Rectal Neoplasms / genetics*
  • Rectal Neoplasms / pathology
  • Succinate Dehydrogenase / genetics*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • SDHD protein, human
  • Imatinib Mesylate
  • Succinate Dehydrogenase
  • Proto-Oncogene Proteins c-kit
  • Receptor, Platelet-Derived Growth Factor alpha

Supplementary concepts

  • Carney-Stratakis Syndrome